Japanese Firms Pursued Over Edirol Ingredient
Chugai Files Further Suit Over Eldecalcitol Against Nichi-Iko, Nissan And Sawai
Chugai is pursuing further Japanese litigation over generic rivals to its Edirol brand, this time concerning the eldecalcitol ingredient produced by Nissan Chemical.
You may also be interested in...
Sawai has followed-up on a raft of approvals announced earlier this year with launch plans, including for the first generics of Daiichi Sankyo’s Memary (memantine hydrochloride) Alzheimer’s disease treatment in three presentations.
Sawai and Nichi-Iko are in the crosshairs of Chugai after the originator filed a lawsuit in Japan claiming patent infringement over the pair’s generic eldecalcitol versions of its Edirol brand.
Sawai has received a raft of generics approvals from Japan’s Ministry of Health, Labour and Welfare, including approval for a tadalafil rival to Cialis and 10 first-time generic approvals.